Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(4):263-266,287
DOI: 10.5428/pcar20190407
Clinical efficacy of alprostadial combined with recombinant human epidermal growth factor in the treatment of refractory diabetic foot
1. LIU Yong(Department of Burn Plastic Surgery,Liu’an People’s Hospital of Anhui Province,Anhui Liu’an 237005,China gerille123@sina.com)
2. ZHAO Zunjiang(Department of Burn Plastic Surgery,Liu’an People’s Hospital of Anhui Province,Anhui Liu’an 237005,China )
3. ZHANG Baode(Department of Burn Plastic Surgery,Liu’an People’s Hospital of Anhui Province,Anhui Liu’an 237005,China )
4. ZHANG Rongtao(Department of Burn Plastic Surgery,Liu’an People’s Hospital of Anhui Province,Anhui Liu’an 237005,China )
ABSTRACT  Objective: To investigate the clinical efficacy of alprostadial combined with recombinant human epidermal growth factor(rh-EGF) in the treatment of refractory diabetic foot.Methods: A total of 110 patients with refractory diabetic foot admitted in the People’s Hospital of Liu’an City,Anhui Province from September 2014 to September 2017 were enrolled in the study.The patients were randomly divided into the observation group and the control group,each consisting of 55 patients.Patients in the control group were treated with rh-EGF alone,while the patients in the observation group were treated with alprostadial combined with rh-EGF.The therapeutic effects,ankle-brachial index,bilateral dorsal artery blood flow velocity and the expression of Bcl-2 and Bax were compared between the two groups.The rate of aderverse drug reactions (ADRs) was compared between the two groups.Results: The therapeutic efficacy of the observation group was significantly higher than that of the control group (90.0% vs 78.2%,P<0.001).The ankle-brachial index and bilateral dorsal artery blood flow velocity were significantly higher than those before treatment,and the detected indexes of the observation group were significantly higher than those of the control group with statistical significance (P<0.05).After treatment,the expression of Bcl-2 in the two groups was all higher than that before treatment,while the expression of Bax was lower than that before treatment(P<0.05).There were no significant ADRs in the two groups,and the rate of ADRs was not statistically different.Conclusion: The treatment of refractory diabetic foot with alprostadial combined with rh-EGF is effective,could enhance the expression of Bcl-2,inhibit the expression of Bax,thus promoting wound healing.For this reason,it is worth further clinical application.
Welcome to PCAR! You are the number 79 reader of this article!
Please cite this article as:
LIU Yong,ZHAO Zunjiang,ZHANG Baode,ZHANG Rongtao,. Clinical efficacy of alprostadial combined with recombinant human epidermal growth factor in the treatment of refractory diabetic foot[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(4): 263-266,287.
References:
1. LE Zhonghong,TANG Xiaojiao,CUI Tingting,et al.Pathogenic bacteriological characteristics and drug resistance of patients with diabetic foot[J].Chin J Nosocomiol,2017,27(3):590-592.In Chinese with English abstract.
2. ZHANG Xiangyun,DING Xiaobin,LIN Xiufeng,et al.Clinical observation of recombinant human epidermal growth factor combined with lipoic acid in the treatment of diabetic foot[J].China Pharmacy,2016,27(29):4147-4149.In Chinese with English abstract.
3. WU Jun,TANG Huiqin,LIU Qun,et al.Alpha-lipoic acid protects fibroblasts from oxidative damage via inhibiting miR-29b expression[J].J Clin Intern Med,2016,33(9):637-640.In Chinese with English abstract.
4. Chinese Society of Diabetes.Guidelines for the prevention and treatment of type 2 diabetes in China(2013 ed)[J].Chin J Metab,2014,22(8):2-42.In Chinese.
5. DI Tietao,ZHANG Chunling,CHEN Lu,et al.Pathogenesis of diabetic foot ulcer and analysis of the causes of impaired healing[J].J Guiyang Univ Chin Med,2017,39(1):98-101.In Chinese with English abstract.
6. ZHU Wanbo.Research progress of the mechanism and treatment of diabetic non-healing wounds[J].Chin J Diabet,2016,24(12):1135-1139.In Chinese with English abstract.
7. Choi S M,Lee K M,Kim H J,et al.Effects of structurally stabilized EGF and bFGF on wound healing in type Ⅰ and type Ⅱ diabetic mice[J].Acta Biomater,2018,1(66):325-334.
8. QU Jianjiao,QU Jianhui,JIN Xueyan,et al.The situation of alprostadil in treatment of diabetic foot[J].China Mod Doc,2016,54(15):164-168.In Chinese with English abstract.
9. SHAO Licheng,YAN Wen,LI Zanzhao,et al.Clinical observation of intravenous drip of alprostadil combined with acupuncture in the treatment of diabetic foot ulcer[J].China Pharmacy,2017,28(20):2796-2799.In Chinese with English abstract.
10. Kang M K,Park S H,Kim Y H,et al.Chrysin ameliorates podocyte injury and slit diaphragm protein loss via inhibition of the PERK-elF2α-ATF-CHOP pathway in diabetic mice[J].Acta Pharmacol Sin,2017,38(8):1129-1140.
11. ZHANG Huiling,ZHANG Chunyang,CHAO Ying,et al.Effect of alprostadil on the expression of Bax and Bcl-2 in retinal tissues of rats with diabetic mellitus[J].Pract Prev Med,2016,23(12):1519-1522.In Chinese with English abstract.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口